Increase of HDL-associated platelet-activating-factor acetylhydrolase (PAF-AH) activity but not of paraoxonase (PON1) during haemodialysis

被引：0
|
作者：
Liberopoulos, E
Papavasiliou, E
Tzallas, C
Katopodis, K
Gouva, C
Christidis, D
Tselepis, A
Siamopoulos, K
Elisaf, M
机构：
[1] Univ Ioannina, GR-45110 Ioannina, Greece
[2] Univ Hosp Ioannina, Ioannina, Greece
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2003年 / 4卷 / 02期
关键词：
D O I：
10.1016/S1567-5688(03)91444-9
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：336 / 336
页数：1
相关论文
共 50 条
  • [21] Paraoxonase lactonase activity (PON-HTLase), asymmetric dimethylarginine (ADMA) and platelet activating factor-acetylhydrolase (PAF-AH) activity in non-obese women with PCOS
    Bayrak, Tulin
    Dursun, Polat
    Bayrak, Ahmet
    Gultekin, Murat
    Kolusari, Ali
    Cakir, Erdinc
    Ozyurt, Merve
    Zeyneloglu, Hulusi B.
    GYNECOLOGICAL ENDOCRINOLOGY, 2012, 28 (11) : 874 - 878
  • [22] S-Glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity
    Rozenberg, Orit
    Aviram, Michael
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 351 (02) : 492 - 498
  • [23] Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2)
    Stafforini, Diana M.
    CARDIOVASCULAR DRUGS AND THERAPY, 2009, 23 (01) : 73 - 83
  • [24] Reduced levels of HDL-associated PAF-acetylhydrolase activity in normolipidemic and dyslipidemic PON1 55LL carriers
    Kakafika, A
    Tambaki, A
    Lourida, E
    Xenofontos, S
    Tsimihodimos, V
    Kalaitzidis, R
    Cariolou, M
    Elisaf, M
    Tselepis, A
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 77 - 77
  • [25] Biology of Platelet-activating Factor Acetylhydrolase (PAF-AH, Lipoprotein Associated Phospholipase A2)
    Diana M. Stafforini
    Cardiovascular Drugs and Therapy, 2009, 23 : 73 - 83
  • [26] Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in patients with hyperbilirubinemic hepatobiliary disease
    Kamisako, T
    Takeuchi, K
    Ito, T
    Tamaki, S
    Kosaka, T
    Adachi, Y
    HEPATOLOGY RESEARCH, 2003, 26 (01) : 23 - 27
  • [27] Platelet-activating factor acetylhydrolase (PAF-AH) in patients with chronic renal failure.
    Hasselwander, O
    Young, IS
    McMaster, D
    Fogarty, DG
    Nicholls, DP
    Maxwell, AP
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A2881 - A2881
  • [28] Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese
    Kosaka, T
    Yamaguchi, M
    Miyanaga, K
    Mizuno, K
    CLINICA CHIMICA ACTA, 2001, 312 (1-2) : 179 - 183
  • [29] VLDL triglycerides inhibit HDL-associated paraoxonase 1 (PON1) activity: in vitro and in vivo studies
    Rosenblat, Mira
    Ward, Sarah
    Volkova, Nina
    Hayek, Tony
    Aviram, Michael
    BIOFACTORS, 2012, 38 (04) : 292 - 299
  • [30] Effect of chronic administration of L-name on paraoxonase (PONI) and platelet activating factor-acetylhydrolase (PAF-AH) activities in the rat
    Beltowski, J.
    Wojcicka, G.
    Marciniak, A.
    Jamroz-Wisniewska, A.
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (01) : 87 - 87
12345